The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds

被引:89
作者
Morphy, Richard [1 ]
机构
[1] Dept Med Chem, Organon Labs, Newhouse ML1 5SH, Lanark, Scotland
关键词
D O I
10.1021/jm0512185
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The target families of greatest interest in drug discovery can be differentiated on the basis of the physicochemical properties of their pre-clinical ligands. The ligands for peptidergic targets, such as peptide GPCRs and integrin receptors, possess significantly higher median property values than those for aminergic targets, such as monoamine transporters and GPCRs. The ligands for peptide GPCRs were found to be less efficient, in terms of their binding energy per unit of molecular weight or lipophilicity, than ligands for monoamine GPCRs. The changes in the property values during the optimization process were found to vary only slightly across the target families, with the main determinant of the drug-likeness of the optimized compounds being the profile of the starting compounds. Agonists for monoamine GPCRs, opioid receptors and ion channels were typically smaller and less lipophilic than the antagonists, but there was no difference between the agonists and the antagonists for peptide GPCRs and nuclear receptors.
引用
收藏
页码:2969 / 2978
页数:10
相关论文
共 21 条
[1]   Oral delivery of G protein-coupled receptor modulators: An explanation for the observed class difference [J].
Beaumont, K ;
Schmid, E ;
Smith, DA .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (16) :3658-3664
[2]   Can peptides be mimicked? [J].
Beeley, NRA .
DRUG DISCOVERY TODAY, 2000, 5 (08) :354-363
[3]   DRUGS FROM EMASCULATED HORMONES - THE PRINCIPLE OF SYNTOPIC ANTAGONISM [J].
BLACK, J .
SCIENCE, 1989, 245 (4917) :486-493
[4]  
BLAKE JF, 2003, BIOTECHNIQUES, V34, pS16
[5]   Recognition of privileged structures by G-protein coupled receptors [J].
Bondensgaard, K ;
Ankersen, M ;
Thogersen, H ;
Hansen, BS ;
Wulff, BS ;
Bywater, RP .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (04) :888-899
[6]   A rule of three for fragment-based lead discovery? [J].
Congreve, M ;
Carr, R ;
Murray, C ;
Jhoti, H .
DRUG DISCOVERY TODAY, 2003, 8 (19) :876-877
[7]   Molecular complexity and its impact on the probability of finding leads for drug discovery [J].
Hann, MM ;
Leach, AR ;
Harper, G .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2001, 41 (03) :856-864
[8]   Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs [J].
Kelder, J ;
Grootenhuis, PDJ ;
Bayada, DM ;
Delbressine, LPC ;
Ploemen, JP .
PHARMACEUTICAL RESEARCH, 1999, 16 (10) :1514-1519
[9]  
Klabunde T, 2002, CHEMBIOCHEM, V3, P929, DOI 10.1002/1439-7633(20021004)3:10<928::AID-CBIC928>3.0.CO
[10]  
2-5